Preclinical evaluation of drugs to block inflammation-driven preterm birth

Area of Science:

• Obstetrics and Gynecology
• Reproductive Biology
• Pharmacology

Background:

• Intrauterine inflammation is a primary driver of early preterm birth, stemming from microbial or sterile causes.
• Understanding and mitigating this inflammation is crucial for improving pregnancy outcomes.

Purpose of the Study:

• To evaluate the anti-inflammatory effects of five drugs on human extraplacental membranes in a preterm labor model.
• To identify potent therapeutic agents for managing intrauterine inflammation.

Main Methods:

• A Transwell model using human extraplacental membranes from preterm labor (30-34 wk) was employed.
• Five drugs, including TPCA1 (IKKβ inhibitor) and OxZ (TAK1 inhibitor), were tested for their ability to reduce inflammatory mediators (IL-6, TNF-α, MCP-1, IL-1β, PGE2) and mRNA expression (IL6, TNFA, PTGS2).
• Data were analyzed using mixed models, comparing effects in membranes with and without histological chorioamnionitis.

Main Results:

• TPCA1 and OxZ demonstrated the most significant anti-inflammatory efficacy, inhibiting 4/5 pro-inflammatory mediators and 2/3 mRNA levels.
• The effectiveness of the drugs was consistent, irrespective of the presence of histological chorioamnionitis.
• Baseline inflammatory marker production was similar between membranes with and without histological chorioamnionitis.

Conclusions:

• TPCA1 and OxZ are highly effective in reducing key pro-inflammatory mediators and gene expression in the context of intrauterine inflammation.
• Combined treatment with TPCA1 or OxZ and antibiotics may offer a strategy to mitigate adverse effects associated with intrauterine inflammation during pregnancy.